NYSE:PTN Stock Quote

Last Price0.6621

Change-0.0379 (-5.41%)

Palatin Technologies is a biopharmaceutical company focused on the development of innovative therapies for a range of medical conditions, including sexual health disorders and other areas with unmet therapeutic needs

The company primarily works on peptide-based drug candidates, leveraging its proprietary technologies to create treatments that target specific physiological pathways. Palatin is committed to advancing its development programs through rigorous research and clinical trials, with the aim of providing effective solutions for patients and improving overall health outcomes.

Palatin Technologies’ Obesity Drug Receives FDA Orphan Designation; Phase 2 Results Imminent (NYSE: PTN)

In an exciting development for the biopharma market, Palatin Technologies (NYSE: PTN)* announced that it has secured FDA orphan drug designation for PL7737, its oral melanocortin-4 receptor (MC4R) agonist, targeting obesity caused by leptin receptor deficiency. According to the company, this designation offers Palatin significant benefits, including tax credits, fee waivers, and potential seven-year market exclusivity upon approval. The company has begun toxicology studies with plans to submit an IND in Q4 2025 and expects clinical data in early 2026.

Via AB Newswire · March 27, 2025

Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.

Cosette Pharmaceuticals, Inc. (“Cosette”), a US-based specialty pharmaceutical company with a focus on women’s health and cardiovascular medicines, has completed the acquisition of Vyleesi® from Palatin Technologies, Inc. (NYSE: PTN), which includes 5 Orange Book listed patents with protection up to 2041. Palatin and Cosette will ensure continued patient and healthcare professional access to Vyleesi® throughout the transition period.

By Cosette Pharmaceuticals, Inc. · Via Business Wire · January 3, 2024

Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

Via FinancialNewsMedia · October 19, 2023

Biotech Market Update: Global Pharmaceuticals Market Expected to Reach $1.5 Trillion by Year’s End

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:CRDF),(NASDAQ:BDRX),(NASDAQ:DRUG),(NYSE:LLY) EQNX::TICKER_END

Via FinancialNewsMedia · August 9, 2023